Related Experiment Video
Updated: Feb 7, 2026
Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
Published on: January 31, 2025
Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs
1California Pacific Medical Center Research Institute, 2333 Buchanan St., San Francisco, CA, 94115, USA.
Abstract:
Malignant melanoma is generally chemo- and radio-resistant, and patients with advanced melanoma have a poor prognosis. However, with our increased understanding of the checkpoint immune molecules and genetic alterations of melanoma cells, more effective immunotherapy, such as anti CTLA4 antibody and anti PD-1 antibodies, and targeted drug therapy, such as BRAF inhibitors and MEK inhibitors, have been developed, resulting in improved overall survival and quality of life of patients with advanced melanoma. In addition, emerging technologies to develop prognostic and predictive biomarkers for response to systemic therapy could help clinicians make more accurate assessments of the disease and formulate more effective treatment plans. In this review, current standard systemic therapy options and recently developed novel drugs for advanced melanoma are discussed.
Insights
Advanced melanoma treatments are improving survival. Immunotherapy (anti-CTLA4, anti-PD-1) and targeted drugs (BRAF, MEK inhibitors) offer new hope. Biomarker research aids personalized treatment plans for better outcomes.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Malignant melanoma exhibits resistance to traditional chemotherapy and radiotherapy.
- Advanced melanoma patients historically face a poor prognosis.
- Recent advancements focus on understanding melanoma's immune checkpoints and genetic mutations.
Purpose of the Study:
- To review current standard systemic therapies for advanced melanoma.
- To discuss novel drug developments in melanoma treatment.
- To highlight the role of emerging biomarkers in predicting treatment response.
Main Methods:
- Literature review of current and emerging treatments for advanced melanoma.
- Analysis of immunotherapies targeting immune checkpoint molecules (e.g., CTLA4, PD-1).
- Evaluation of targeted therapies, including BRAF and MEK inhibitors.
Main Results:
- Immunotherapy (anti-CTLA4, anti-PD-1 antibodies) and targeted therapies (BRAF, MEK inhibitors) have improved survival and quality of life.
- Understanding of melanoma's genetic landscape and immune evasion mechanisms has driven therapeutic innovation.
- Emerging prognostic and predictive biomarkers are crucial for optimizing systemic therapy selection.
Conclusions:
- Systemic therapies, particularly immunotherapy and targeted drugs, have significantly advanced the management of advanced melanoma.
- Personalized medicine approaches, guided by biomarkers, are essential for effective melanoma treatment.
- Continued research into novel agents and biomarkers promises further improvements in patient outcomes.
Related Concept Videos
01:28Drug Therapy
Antianxiety Medications
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
00:59Gene Therapy
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.